DRAXXIN® (tulathromycin) Injectable Solution is a unique, novel treatment that delivers:- Superior efficacy to treat BRD when compared with Baytril®, Nuflor® and Micotil® in field studies.1,2,3,6
- Convenient, full course of therapy in a single dose.
- Effectiveness against the four major BRD pathogens.
- Mannheimia (Pasteurella) haemolytica
- Pasteurella multocida
- Histophilus somni (Haemophilus somnus)
- Mycoplasma bovis
- Excellent first BRD treatment response.1,2,3,6
- Remarkably lower mortalities and chronics due to BRD.1,2,3
- Effective control of BRD in cattle at high risk of developing BRD.3
DRAXXIN, tulathromycin, is the first entry of a novel macrolide subclass, the triamilides, developed by Pfizer Animal Health. DRAXXIN is now the first-line product-of-choice to treat pneumonia, offering both superior disease treatment as well as outstanding efficacy for the control of pneumonia in cattle at high risk of developing the disease.
A single, subcutaneous injection of 1.1 mL/100 lb. (2.5 mg/kg) of bodyweight delivers a full course of therapy, thereby minimizing labor and handling stress. More...
References and Footnotes
| Copyright © 2008 Pfizer Inc. All rights reserved. |  |
 |
Back to top | Site Map | Privacy & Use | Help | Contact Us |
 |
The product information provided in this site is intended only
for residents of the United States. The products discussed herein may
have different product labeling in different countries. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. |